⌕
Anbio Biotechnology · NNNN · Nasdaq
Tenet 37 · Weak
Compare
$3.65−5.93%At closeTenet 37 · Weak
$3.65−0.23 (−5.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Anbio Biotechnology (NNNN) Stock

Anbio Biotechnology (NNNN) closed at $3.65 on Nov 17, 2026; its Tenet Score is 37 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

36 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$3.65
Nov 17, 2026
Market cap
$558.3M
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
87.2×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
52-week range
3.09 – 44.73
low → high · as of close, Nov 16, 2026
Tenet Score
37/100
Weak · 340 Healthcare peers

Industry: In Vitro, in Vivo Diagnostic Substances

Anbio Biotechnology scores 37/100. Weak. Strongest on financial health, growth is the soft spot, trading at 87× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
37/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
8
Quality
57
Health
82
Growth
1

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthBGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
18.5×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/S
64.6×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
27%
fiscal year to Dec 31, 2025
Operating margin
—
Not meaningful: revenue is too small to measure a margin against.
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
—
Withheld: this figure is outside the range we accept for its kind.
Net debt / EBITDA
−2.1×
fiscal year to Dec 31, 2025
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift toward…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 1 US ETFs · top wrappers by weightSee all ETFs holding NNNN →

Similar-sized companies in In Vitro, in Vivo Diagnostic Substances

The 1 company in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
QuidelOrtho CorporationQDEL44$701.4M

What sector and industry is Anbio Biotechnology in?

Anbio Biotechnology is in the Healthcare sector and the In Vitro, in Vivo Diagnostic Substances industry.

What is Anbio Biotechnology's Tenet Score?

Anbio Biotechnology's Tenet Score is 37 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.